Insider Transactions in Q4 2022 at Terns Pharmaceuticals, Inc. (TERN)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 23
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
137,931
+2.75%
|
$965,517
$7.25 P/Share
|
|
Dec 23
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
137,931
+2.75%
|
$965,517
$7.25 P/Share
|
|
Dec 23
2022
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Indirect |
758,620
+14.88%
|
$5,310,340
$7.25 P/Share
|
|
Dec 23
2022
|
Vivo Opportunity, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
758,620
+14.88%
|
$5,310,340
$7.25 P/Share
|
|
Nov 30
2022
|
Senthil Vel Sundaram Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3
+0.04%
|
$3
$1.41 P/Share
|
|
Nov 30
2022
|
Mark J. Vignola Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3
+0.04%
|
$3
$1.41 P/Share
|
|
Nov 30
2022
|
Seokho Bryan Yoon COO and General Counsel |
BUY
Open market or private purchase
|
Direct |
3
+0.04%
|
$3
$1.41 P/Share
|
|
Nov 23
2022
|
Lav Biosciences Fund V, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,500,000
-39.67%
|
$7,500,000
$5.5 P/Share
|